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Aims: Somatic mutations in IDH1 and IDH2 are described in glioblastomas (GBMs). 
Mutant IDH1 and IDH2 reduce α-KG to D-2HG which accumulates, and is proposed to 
promote tumorigenesis. HOT catalyzes the conversion of γ-hydroxybutyrate to succinic 
semialdehyde in a reaction that produces D-2HG. Since increased HOT enzyme activity 
could lead to an accumulation of D-2HG, coupled with the fact that only a minority 
of GBMs carry IDH1/2 mutations and 2HG accumulation has recently been described 
in IDH wild-type tumors, we analyzed a set of GBM samples for mutations in the HOT 
gene. Materials & methods: We screened 42 human GBM samples for mutations in 
HOT. Results: No mutations in HOT were identified in the 42 GBM samples screened. 
Conclusion: Mutations in the coding regions of HOT do not occur at an appreciable 
frequency in GBM.
Genetic changes in genes called IDH have been shown to occur regularly in brain 
tumors. These changes result in the production of a chemical called D-2HG which 
accumulates to a high level in cells and is thought to damage normal cells, causing 
them to become cancer cells. Genetic changes in other genes may also result in the 
production of D-2HG and cause cancer in the same way as changes in IDH do. One such 
gene is called HOT. This study investigated whether genetic changes in HOT could be 
found in brain tumors.
Keywords: α-ketoglutarate • 2-hydroxyglutarate • brain • glioblastoma • glioma 
• hydroxyacid-oxoacid transhydrogenase • isocitrate dehydrogenase • metabolism • mutation
Gliomas are a diverse group of tumors with 
respect to morphology, genetic status and 
prognosis and account for 70% of all pri-
mary CNS neoplasms. WHO grade II and 
III gliomas are invasive and typically prog-
ress to higher-grade lesions with poor out-
come. Glioblastoma (GBM) represents the 
commonest glioma and may develop in the 
absence of a less malignant precursor (pri-
mary GBM), or through progression from a 
lower-grade tumor (secondary GBM). GBM 
carries a very poor prognosis [1,2].
Somatic mutations in genes encoding the 
enzymes IDH1 and IDH2 have been identi-
fied through genome-wide sequencing stud-
ies in approximately 70% of grade II and 
III gliomas, and in approximately 5% of 
GBMs [3,4], (for a review see [5]). These muta-
tions are early events in gliomagenesis [6], 
which are associated with a relatively favor-
able prognosis [7], and may be clinically use-
ful as diagnostic [8,9] and predictive biomark-
ers [10], as well as potential therapeutic targets 
in the future [11]. Mutations in IDH1/2 also 
occur in patients with acute myeloid leu-
kemia (AML) [12], angioimmunoblastic 
T-cell lymphoma (AITL) [13] and other solid 
tumors [14–19].
IDH1 and IDH2 are homodimeric 
enzymes that catalyze the oxidative decar-
boxylation of isocitrate to α-KG and reduce 
NADP to NADPH. IDH1 is localized to the 
cytoplasm and peroxisome [20], where it serves 
as a major source of cytosolic NADPH, plays 
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a role in cellular metabolic processes [21,22], and pro-
tects against oxidative stresses [23]. IDH2 is localized to 
the mitochondrion where its main function is to regu-
late the tricarboxylic acid cycle [20]. A third enzyme, 
IDH3, is also localized to the mitochondrion and plays 
a key role in tricarboxylic acid cycle function.
Pathogenic mutations in IDH1 and IDH2 are het-
erozygous somatic missense changes that almost 
always occur at a single, specific residue at the enzyme 
active site. Mutations in IDH1 generally affect argi-
nine 132 (R132) [3], which is commonly substituted 
for histidine (R132H), but mutations of R132 to ser-
ine, cysteine, glycine, leucine and lysine have also been 
identified [4,24]. Moreover, mutations in IDH1 occur-
ring at arginine 100 (R100), which may also be patho-
genic [19,24–25] have also been identified in gliomas. 
Mutations in IDH2 affect arginine 172 (R172) and 
arginine 140 (R140), the former being analogous to 
IDH1 R132 and the latter to IDH1 R100 [4,26]. Muta-
tions in the active site arginine residues possess neo-
enzymatic activity, which results in the reduction of 
α-KG to D-2HG [19,26–28], which accumulates at high 
levels in IDH1- and IDH2-mutated tumors [26,27]. It 
has been stated that D-2HG acts as an oncometabolite, 
with numerous potential protumorigenic effects, most 
likely as a result of its ability to competitively inhibit 
α-KG-dependent enzymes [29,30]. Moreover, a direct 
correlation between the amount of 2HG produced by 
mutant IDH1/2 and the characteristics of the result-
ing tumor seems to exist, since patients with IDH2 
R140-mutant AML produce lower levels of D-2HG 
and have a better prognosis those with IDH2 R172 
mutations [19].
Out of the 60 or more, α-KG-dependent enzymes 
in human cells, particular interest has centered on 
the inhibition by D-2HG of HIF-PHD, the Jumonji-
C domain containing histone demethylases, the 
Ten-Eleven Translocation family of 5-methylcyto-
sine hydroxylases and collagen prolyl 4-hydroxlase. 
Inhibition of these enzymes could lead to tumor 
formation by causing HIF1α target gene overexpres-
sion [29,31–32], histone modifications [29,33], aberrant 
DNA methylation [29–30,34–36] and abnormal collagen 
maturation [29,32], respectively.
D-2HG normally functions as an intermediate in 
the production of 5-aminolevulinate and porphyrin 
in heme synthesis [37,38]. Our current understanding 
of the cellular metabolism of D-2HG is limited, but 
two enzymes, D-2HGDH and HOT are known to 
affect its cellular levels [39,40]. In fact, early studies per-
formed on mitochondrial fraction of rat kidney, liver 
and brain demonstrated that D-2HG is produced from 
the activity of HOT, which catalyzes the conversion 
of GHB to SSA, with a stoichiometric production of 
D-2HG from α-KG [41], (for a review see [42]), and the 
existence of HOT in humans was then demonstrated 
in homogenates of human liver, lymphoblast and 
fibroblasts [43,44]. D-2HG produced by HOT is sub-
sequently interconverted to α-KG via the activity of 
D-2HGDH, in order to maintain carbon balance.
Homozygous inactivating mutations in D-2HGDH 
lead to D-2HG accumulation in tissues, resulting in 
the neurological condition hereditary D-2-hydroxy-
glutaric aciduria (D-2-HGA) [43]. D-2-HGA is associ-
ated with developmental delay, hypotonia and seizures, 
but not an increased risk of brain tumors. Conversely, 
l-2-hydroxyglutaric aciduria, which occurs due to inac-
tivating mutations in L-2HGDH, is weakly associated 
with the development of brain tumors [45]. Germline 
IDH2 mutations affecting arginine 140, have also been 
reported in patients with D-2-HGA carrying wild-type 
(WT) D2HGDH [46]. However, we and others have not 
identified D2HGDH mutations in gliomas [47,48]. Mass 
isotopomer studies in patients with the D-2-HGA have 
demonstrated that accumulated D-2HG derives from 
mitochondrial α-KG [49], and it has been suggested 
that alterations in HOT activity may be involved in the 
excess D-2HG production observed [41,44,50–51]. How-
ever enzyme activity assays in fibroblast homogenates 
from patients with D-2-HGA demonstrated normal 
HOT activity [44].
Nevertheless, potential evidence for the ability of 
increased HOT activity to result in excess D-2HG pro-
duction comes from the observation of patients with 
the hereditary disorders SSADH deficiency [52], and 
α-ketoglutarate dehydrogenase deficiency [53]. In addi-
tion to GHB, considerably increased levels of D2HG 
were observed in body fluids of some patients affected 
by SSADH deficiency, and consequently in this disease 
elevated intracellular GHB levels are thought to drive 
HOT enzyme activity to produce secondary increased 
levels of D2HG [52]. Interestingly, D2HG also accu-
mulates in the brain, liver and kidney of SSADH-defi-
cient mice, showing a consistent link between SSADH 
deficiency and D2HG accumulation [54]. In patients 
with α-ketoglutarate dehydrogenase deficiency accu-
mulated α-KG is thought to alter the kinetic equilib-
rium of HOT [53] and may provide an explanation for 
the elevated urinary 2HG levels observed in this condi-
tion [55,56]. Furthermore, siRNA directed inhibition of 
HOT function has been shown to reduce cellular 2HG 
levels in vitro [57].
Interestingly, 2HG has recently been shown to 
accumulate at high levels in a subset of IDH WT 
gliomas, using magnetic resonance spectroscopy [58]. 
Furthermore, 2HG has been shown to accumulate at 
millimolar concentrations in IDH WT breast cancer 
tissues, in association with MYC gene expression [57]. 
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These findings raise the possibility that mechanisms 
of 2HG accumulation unrelated to IDH mutation may 
exist in gliomas.
Since an increase in HOT enzyme activity could 
lead to an accumulation of D-2HG, with tumorigenic 
effects similar to those observed in tumors with mutant 
IDH1/2 and 2HG has recently been shown to accumu-
late at high concentrations in IDH WT tumors, cou-
pled with the fact that only a minority of GBMs carry 
IDH1/2 mutations, we analyzed a set of GBM samples 
for mutations in the HOT gene.
Materials & methods
Sample collection
All brain tumors were obtained from the neuropathol-
ogy department at The Royal Free Hospital, Hamp-
stead, London. All 42 samples analyzed were confirmed 
to be WHO grade IV glioblastoma. We have worked 
solely on anonymous samples. Study of these has been 
approved by Oxfordshire REC B 05/Q1605/66.
DNA extraction
DNA was extracted from paraffin embedded samples 
using DNeasy Blood and Tissue from QuiagenR 
(CA, USA), following the manufacturer’s instructions.
Sequencing analysis
Mutation screening of each gene was performed by 
direct sequencing of genomic DNA in forward and 
reverse orientations using the Applied Biosystems 
BigDye terminator reaction kit and the AB 3730xl 
sequencing machine (Applied Biosystems, CA, USA). 
Primer sequences were designed to encompass all 
14 exons of HOT (RefGene:NM_144650). Primer 
sequences are illustrated in Table 1. PCR conditions 
are available on request.
Results
We screened 42 primary glioblastomas (WHO grade 
IV) for mutations in the 14 exons of HOT. Four of these 
tumors were known from previous analysis to carry 
IDH1 R132H mutations, but none carried mutations in 
IDH2, IDH3, L2HGDH or D2HGDH [47]. No somatic 
mutations were identified in HOT. One previously 
described missense single nucleotide polymorphism 
(GCC->GTC) was identified in exon 1 of HOT.
Conclusion & future perspective
We conclude that mutations in the coding regions of 
HOT do not occur at an appreciable frequency in IDH 
WT GBM. The fact that IDH mutations occur more 
frequently in grade II and grade III glioma than in 
GBM raises the possibility that HOT mutations may 
also be identified in earlier grade tumors than those 
included in this study.
It is also feasible, however, that although mutations 
in the coding region of HOT were not identified in 
the IDH WT GBM patients who were studied, other 
genetic changes with the potential to increase HOT 
activity might exist in these tumors. For example, 
copy number variations encompassing HOT could 
occur, thus increasing gene expression. Indeed interest-
ingly, several large copy number variations have been 
described encompassing the HOT gene, including one 
linked to AML [59]. Alternatively, mutations in possibly 
uncharacterized regulatory regions of HOT, such as 
Table 1. Primer sequences encompassing the 14 exons of HOT.
Exon Forward primer Reverse primer 
1 TGGCTTGAGGCTTAGACAGG AAGACTGCGCAGGATCTGA
2 TGCCAAGAACTACCAATTTGA GCCAAATGCAGAAACCAAAA
3 TGTTCACTGCTGGATTTTACTATCA TGGTCTGATCAAATAGAGATTATGGA
4 ATGGACTGGCCAACTCTCAA CTTCTGGCAAACTCACGTTG
5 GCAGTTCTAGTGGAGTTGAACCTA GCTTCTGCTTAAAGTAAAGAAACAA
6 GGCATGGCAATTTATTTCTGA CTCATTGCAAAATAAAACAAACA
7 TTTCCTTCTCTAATTTTGTTCCTCA TGGAGTTGAAAGGTAAGGGAGA
8 AATGATGCCCATGGCTTTAG TGTGCGTTGAGCAACAAAAT
9 GAGGAAGATGACGCTTTCCA TGTGGGCCTCCTGTTCTATT
10 AGGAATTGCCAATGTTGATG AAATTTTACCACCTGTCCTGAA
11 GCATCCCCATAAGAGTATCTTTC TCTAAGCAGGCGAGAATTGG
12 CAGGGAAGAACAGCTTTGTCA CTCCCAAAATGCTGGGATTA
13 AGAGCCCGTTTCTTCCTCTC CTCCTTCGCAGGGAGTGA
14 CTTTTCAAAGCCCTGGGTAA TCAGCTCTTGCTCTCAGCAC
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the binding sequence for transcriptional repressors or 
activators, or epigenetic changes such as alterations 
of promoter methylation could occur and result in an 
increase in HOT transcriptional activity. Interestingly, 
promoter hypermethylation affecting HOT transcrip-
tional activity has been identified in colorectal cancer, 
although in this case, this led to a downregulation in 
HOT expression [60].
It remains to be seen if mechanisms of 2HG accu-
mulation unrelated to IDH mutation exist in gliomas. 
However, in view of the fact that 2HG has recently 
been shown to accumulate in IDH WT tumors, addi-
tional studies are required to identify pathogenic muta-
tions in HOT and other candidate genes such as MYC, 
which may have the potential to increase D-2HG pro-
duction and result in cellular effects similar to those 
seen in IDH1 and IDH2 mutant tumors.
Therapies targeting mutant IDH1 and IDH2 have 
been developed, which have been shown to block 
D-2HG production and to reverse some of the cellular 
effects associated with mutant IDH expression [61,62]. 
Furthermore, the targeted inactivation of IDH1 R132H 
by the inhibitor AGI-5198 has been shown to impair 
the growth of IDH1-mutant glioma cells and mouse 
xenografts, and promote gliogenic differentiation [63]. 
Although the potential clinical benefit of such inhibi-
tors is not yet clear, their emergence raises new hope for 
the treatment of IDH-mutated tumors. If mutations in 
genes other than IDH1 and IDH2 are indeed discovered 
to have the potential to increase cellular D-2HG levels, 
with protumorigenic effects, then such mutations may 
also serve as potential therapeutic targets in the future.
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Executive summary
•	 Somatic mutations in IDH1 and IDH2 occur in grade II and III gliomas, and primary and secondary 
glioblastomas (GBMs).
•	 Mutant IDH1 and IDH2 exhibit novel enzymatic activity, reducing α-KG to D-2HG, which accumulates.
•	 D-2HG is thought to act as an oncometabolite through its inhibition of α-KG dependent enzymes.
•	 2HG has recently been shown to accumulate in IDH wild-type tumors.
•	 HOT catalyzes the conversion of GHB to SSA in a reaction that converts α-KG to D-2HG.
•	 Mutations in HOT could also therefore potentially lead to D-2HG accumulation and thus to tumorigenesis via 
mechanisms similar to those associated with mutant IDH1/2.
•	 We screened 42 human GBM samples for mutations in the coding regions of HOT, but none were identified.
•	 Hence, we conclude that mutations in the coding region of HOT do not occur at an appreciable frequency in 
GBM.
•	 However, somatic copy number alterations and epigenetic changes such as altered promoter methylation may 
also have the potential to alter HOT activity in glioma.
•	 Additional studies are warranted to identify pathogenic mutations in HOT and other genes which may have 
the potential to increase D-2HG production and result in cellular effects similar to those seen in IDH1 and IDH2 
mutant tumors.
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